Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment

1 Wingerchuk DM Lennon VA Pittock SJ Lucchinetti CF Weinshenker BG . Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485 – 1489 .

2 Lennon VA Wingerchuk DM Kryzer TJ Pittock SJ Lucchinetti CF Fujihara K . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106 – 2112 .

3 Lucchinetti CF Mandler RN McGavern D Bruck W Gleich G Ransohoff RM . A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450 – 1461 .

4 Watanabe S Nakashima I Misu T Miyazawa I Shiga Y Fujihara K Itoyama Y . Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13: 128 – 132 .

5 Nozaki I Hamaguchi T Komai K Yamada M . Fulminant Devic disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry 2006; 77: 1094 – 1095 .

6 Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444 – 1452 .

7 Cree BA Lamb S Morgan K Chen A Waubant E Genain C . An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270 – 1272 .

8 Mandler RN Ahmed W Dencoff JE . Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219 – 1220 .

9 Aguilera AJ Carlow TJ Smith KJ Simon TL . Lymphocytaplasmapheresis in Devic's syndrome. Transfusion 1985; 25: 54 – 56 .